Disparities in antiretroviral treatment: A comparison of behaviorally HIV-infected youth and adults in the HIV Research Network

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 100-107

  Agwu, Allison L ^a,b   Fleishman, John A ^c   Korthuis, P Todd ^d   Siberry, George K ^e   Ellen, Jonathan M ^f   Gaur, Aditya H ^g   Rutstein, Richard ^h   Gebo, Kelly A ^b  

^a Division of Pediatric Infectious Diseases   (United States)

^b Division of Infectious Diseases   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Adolescent; Disparities; HAART; HIV; Youth

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BEHAVIOR; CD4+ T LYMPHOCYTE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; HAZARD RATIO; HEALTH CARE DISPARITY; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; JUVENILE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; NEGRO; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK; STATISTICAL SIGNIFICANCE; ADOLESCENT; AGE; COMPARATIVE STUDY; DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TIME;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 80155174941     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31822327df     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. HIV and AIDS in the United States: A Picture of Today's Epidemic. Available at: www.cdc.gov/hiv/topics/ surveillance. March 2008. Accessed March 4, 2011.
2. Futterman DC. HIV in adolescents and young adults: half of all new infections in the United States. Top HIV Med. 2005;13:101-105.
3. Wilson CM, Wright PF, Safrit JT, et al. Epidemiology of HIV infection and risk in adolescents and youth. J Acquir Immune Defic Syndr. 2010;54(suppl 1):S5-S6.
4. AMFAR. Youth and HIV/AIDS in the United States: Challenges and Opportunities for Prevention. September 2010. Available at: www.amfar.org/ uploadedFiles/In-the-Community/puplications/youth.pdf. Accessed November 15, 2010.
5. Agwu A, Ellen JM, Rutstein R, et al. Disparities in Timing of HAART in Youth Infected Through Risk Behaviors. Pediatric Academic Societies; 2009. Baltimore, MD.
6. Murphy DA, Wilson CM, Durako SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13:27-40. (Pubitemid 32125499)
7. Flynn PM, Rudy BJ, Douglas SD, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:271-279. (Pubitemid 38951966)
8. Blum RW, McNeely C, Nonnemaker J. Vulnerability, risk, and protection. J Adolesc Health. 2002;31:28-39. (Pubitemid 34687079)
9. Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157:249-255. (Pubitemid 36343379)
10. Murphy DA, Belzer M, Durako SJ, et al. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med. 2005;159:764-770. (Pubitemid 41126841)
11. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV71 Infected Adults and Adolescents. Available at: http://aidsinfo.nih.gov. Accessed January 15, 2011.
12. Vessey JA, Miola ES. Teaching adolescents self-advocacy skills. Pediatr Nurs. 1997;23:53-56.
13. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96-103. (Pubitemid 40094126)
14. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr. 2000;25:115-123.
15. Centers for Disease Control and Prevention. HIV/AIDS Surveillance. April 1, 2008. Available at: www.cdc.gov/hiv/topics/surveillance/resources/slides/ index.htm. Accessed November 25, 2010.
16. Gebo KA, Moore RD, Fleishman JA. The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV. Hopkins HIV Rep. 2003;15:5-6.
17. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005;43:III40-III52. (Pubitemid 41329370)
18. Archive of Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://aidsinfo.nih.gov/guidelines/ArchivedGuidelines Accessed April 15, 2010.
19. Greenbaum AH, Wilson LE, Keruly JC, et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS. 2008;22:2331-39.
20. Patterson K, Napravnik S, Eron J, et al. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med. 2007;8:406-410. (Pubitemid 47163274)
21. Silverberg MJ, Leyden W, Horberg MA, et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684-691. (Pubitemid 46598461)
22. Bosch RJ, Bennett K, Collier AC, et al. Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44:268-277. (Pubitemid 46328342)
23. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS. 2008;22:1463-1473.
24. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006;57:4-7. (Pubitemid 43057052)
25. Branas F, Berenguer J, Sanchez-Conde M, et al. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med. 2008;121:820-824.
26. Keruly JC, Conviser R, Moore RD. Association of medical insurance and other factors with receipt of antiretroviral therapy. Am J Public Health. 2002;92:852-857. (Pubitemid 34441643)
27. Rudy BJ, Murphy DA, Harris DR, et al. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDs. 2009;23:185-194.
28. Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157:249-255. (Pubitemid 36343379)
29. Puccio JA, Belzer M, Olson J, et al. The use of cell phone reminder calls for assisting HIV-infected adolescents and young adults to adhere to highly active antiretroviral therapy: a pilot study. AIDS Patient Care STDs. 2006;20:438-444. (Pubitemid 43993098)
30. Parsons GN, Siberry GK, Parsons JK, et al. Multidisciplinary, inpatient directly observed therapy for HIV-1-infected children and adolescents failing HAART: A retrospective study. AIDS Patient Care STDs. 2006;20:275-284.
31. Reisner SL, Mimiaga MJ, Skeer M, et al. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 2009;17:14-25.
32. Johnson RL, Martinez J, Botwinick G, et al. Introduction: what youth need-adapting HIV care models to meet the lifestyles and special needs of adolescents and young adults. J Adolesc Health. 2003;33:4-9. (Pubitemid 36918439)
33. Sawyer SM, Drew S, Yeo MS, et al. Adolescents with a chronic condition: challenges living, challenges treating. Lancet. 2007;369:1481-1489. (Pubitemid 46635756)
34. Palella FJ, Chmiel JS, Moorman AC, et al; the HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16:1617-1626. (Pubitemid 34921107)
35. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003;17:1741-1751. (Pubitemid 37000092)
36. Palella FJ, Baker R, Chmiel JS, et al. Higher Adjusted Mortality Rates Among Publicly Insured Patients and Blacks in the HIV Outpatient Study. 15th Conference on Retroviruses and Opportunistic Infections; February 3, 2008; Boston, MA.
37. Lillie-Blanton M, Stone VE, Snow JA, et al. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health. 2010;100:1493-1499.
38. Keruly JC, Conviser R, Moore RD. Association of medical insurance and other factors with receipt of antiretroviral therapy. Am J Public Health. 2002;92:852-857. (Pubitemid 34441643)
39. Institute of Medicine of the National Academies. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Institute of Medicine. 2003. Available at: www.nap. edu/catalog/10260.htm. Accessed January 25, 2011.
40. Beach MC, Saha S, Korthuis PT, et al. Differences in patient-provider communication for Hispanic compared to non-Hispanic white patients in HIV care. J Gen Intern Med. 2010;25:682-687.
41. Kitahata MM, Van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24:106-114. (Pubitemid 30640955)
42. Yehia BR, Gebo KA, Hicks PB, et al. Structures of care in the clinics of the HIV Research Network. AIDS Patient Care STDs. 2008;22:1007-1013.
43. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296. (Pubitemid 44837777)